John H. Stewart IV: First Completed Randomized Trial with Oncologic Endpoints for Appendiceal Cancer
John H. Stewart IV, MD, MBA, is Chair of Surgery at Morehouse School of Medicine and Associate Dean for Oncology Programs, shared a post on LInkedIn by Annals of Surgical Oncology, adding:
“This work represents the first completed randomized trial with oncologic endpoints for appendiceal cancer, a rare and often under-studied disease.
With 10-year follow-up, we found that both mitomycin C and oxaliplatin demonstrate similar long-term efficacy when used in hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery. Importantly, many patients experience durable survival beyond a decade—an outcome that was once unimaginable for this population.
I am deeply grateful to my co-investigators, patients, and collaborating institutions who made this milestone possible.
This trial underscores the importance of prospective studies in rare cancers, as well as the ongoing need to refine surgical and intraperitoneal therapies to improve outcomes further.
Excited to see how the field of peritoneal surface oncology continues to evolve—through innovations in trial design, translational science, and global collaboration—to expand hope for patients facing these challenging diseases.”
Quoting Annals of Surgical Oncology‘s post:
“Audio Visual Abstract: Ten-Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination, John H. Stewart”
More post featuring John Stewart IV on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023